Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial ...

When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV ...

Moderna's new £150million vaccine factory in Oxfordshire is nearly finished and about to start production. The biotechnology company has invested "millions" in the plant which will create between 150 ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three vaccines available in the U.S.

(Reuters) - Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial officer, Bloomberg Law reported on Tuesday citing one person familiar ...

Pharmaceutical company Moderna (MRNA) has seen its stock slump in recent months. The share price peaked at $150 in early ...

Moderna, Inc. (NASDAQ:MRNA) is a pharmaceutical and biotechnology company specializing in RNA therapeutics, particularly mRNA ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

While the inquiry gets most things right, as vaccine experts, we argue the government response should be broadened in three ...

JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $59 from $70 and keeps an Underweight rating on the shares. The firm updated estimates following Pfizer’s Comirnaty ...